| HOME >> BIOLOGY >> TECHNOLOGY |
Protocols on ImmuneRegen's Homspera(TM) Submitted to RFI, 'Therapeutic
Countermeasures against CDC Category A and B Threat Agents'
SCOTTSDALE, Ariz., Aug. 23 /PRNewswire-FirstCall/ -- Research and development biotechnology company ImmuneRegen BioSciences, Inc. a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO.OB), announced today that it has recently responded to a Request for Information (RFI) from the Defense Threat Reduction Agency (DTRA) of the Department of Defense for Therapeutic Countermeasures against CDC Category A and B Threat Agents. ImmuneRegen made its submission August 20, 2007 with information on its potential treatment, Homspera(TM).
ImmuneRegen filed a formal response to the RFI respective to its compound Homspera(TM), currently in development as a therapeutic and prophylactic countermeasure against multiple pathogens including multiple biological, chemical and radiological threats. For the purposes of this request, the RFI submission focuses primarily on anthrax countermeasures.
"We believe that Homspera is at the forefront of the development of Category A and B countermeasures," commented Michael Wilhelm, co-founder and CEO of ImmuneRegen. "Our studies have shown Homspera to be effective in protecting experimental animals against the lethal effects of ionizing radiation, infection with anthrax spores, infection with influenza virus, and to be an adjuvant in influenza vaccine studies. We believe Homspera's mode of action includes an immunostimulatory activity that results in enhanced host defenses against multiple pathogens."
Should this RFI lead to further studies, ImmuneRegen expects to partner with appropriate governmental agencies, such as USAMRIID (U.S. Army Medical Research Institute for Infectious Diseases) or AFIP (Armed Forces Institute of Pathology).
About Homspera(TM)
Homspera is a generic name used by the Company to describe the
synthetic peptide Sar
'/>"/>
| SOURCE ImmuneRegen BioSciences, Inc. Copyright©2007 PR Newswire. All rights reserved |